Taiwan's disease profile will remain favourable for prescription drugs as the prevalence of chronic diseases continues to grow and authorities work to improve the drug approval process. This will cause a corresponding rise in demand for treatments in therapeutic areas such as cardiovascular diseases, oncology and dementia. A key risk facing multinational drugmakers seeking to commercialise products that target these disease groups will stem from the cost containment measures employed by the National Health Insurance Administration (NHIA). The Taiwanese pharmaceutical market amounted to TWD188.3bn (USD6.2bn) in 2017, accounting for 16.9% of total healthcare spending. It has one of the largest medicine market in the Asia Pacific, with a high per-capita pharmaceutical spending of around USD262. As with most developed countries, prescription drugs are dominant in the market, accounting for 92.5% of total sales in 2017 - the bulk of which (around 70%) came from patented drugs.

Key View

SWOT

Industry Forecast

Pharmaceutical Market Forecast 

Healthcare Market Forecast

Prescription Drug Market Forecast

Patented Drug Market Forecast

Generic Drug Market Forecast

OTC Medicine Market Forecast 

Pharmaceutical Trade Forecast 

Industry Risk/Reward Index

Asia Pacific Innovative Pharmaceuticals & Healthcare Risk/Reward Index

Taiwan Innovative Pharmaceuticals Risk/Reward Index 

Regulatory Development

Regulatory Review

Market Overview

Competitive Landscape

Company Profile

Sanofi

GlaxoSmithKline

Merck & Co 

Novartis 

Pfizer

ScinoPharm Taiwan 

TaiGen

Yung Shin Pharmaceutical

Taiwan Demographic Outlook 

Pharmaceuticals & Healthcare Glossary 

Pharmaceuticals & Healthcare Methodology